<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
  <?properties open_access?>
  <?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName A++V2.4.dtd?>
  <?SourceDTD.Version 2.4?>
  <?ConverterInfo.XSLTName springer2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Eur J Pediatr</journal-id>
      <journal-title-group>
        <journal-title>European Journal of Pediatrics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0340-6199</issn>
      <issn pub-type="epub">1432-1076</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3078321</article-id>
      <article-id pub-id-type="pmid">21479529</article-id>
      <article-id pub-id-type="publisher-id">1452</article-id>
      <article-id pub-id-type="doi">10.1007/s00431-011-1452-3</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Educational paper</article-title>
        <subtitle>The expanding clinical and immunological spectrum of severe combined immunodeficiency</subtitle>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>van der Burg</surname>
            <given-names>Mirjam</given-names>
          </name>
          <address>
            <phone>+31-107-043015</phone>
            <fax>+31-107-044731</fax>
            <email>m.vanderburg@erasmusmc.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gennery</surname>
            <given-names>Andy R.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 50, Rotterdam, 3015 GE The Netherlands </aff>
        <aff id="Aff2"><label>2</label>Department of Pediatric Immunology, Great North Children&#x2019;s Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, UK </aff>
        <aff id="Aff3"><label>3</label>Institute of Cellular Medicine, Child Health, University of Newcastle upon Tyne, Newcastle upon Tyne, UK </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>9</day>
        <month>4</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>9</day>
        <month>4</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2011</year>
      </pub-date>
      <volume>170</volume>
      <issue>5</issue>
      <fpage>561</fpage>
      <lpage>571</lpage>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>2</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>10</day>
          <month>3</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2011</copyright-statement>
      </permissions>
      <abstract id="Abs1">
        <p>Severe combined immunodeficiency (SCID) is one of the most severe forms of primary immunodeficiency characterized by absence of functional T lymphocytes. It is a paediatric emergency, which is life-threatening when recognized too late. The clinical presentation varies from the classical form of SCID through atypical SCID to Omenn syndrome. In addition, there is a considerable immunological variation, which can hamper the diagnosis. In this educational review, we describe the immunopathological background, clinical presentations and diagnostic process of SCID, as well as the therapeutic possibilities.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Severe combined immunodeficiencies</kwd>
        <kwd>Diagnosis</kwd>
        <kwd>Lymphocytes</kwd>
        <kwd>Therapy</kwd>
        <kwd>Primary immunodeficiencies</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2011</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Severe combined immunodeficiency (SCID) is an inherited primary immunodeficiency, which is characterized by the absence or dysfunction of T lymphocytes affecting both cellular and humoral adaptive immunity [<xref ref-type="bibr" rid="CR46">46</xref>]. It is one of the most severe forms of primary immunodeficiency (PID), which is life-threatening when recognized too late. Seven percent of PID patients suffer from a T cell deficiency, including SCID [<xref ref-type="bibr" rid="CR18">18</xref>]. Depending on the genetic defect, B and natural killer (NK) cells may be present or absent. Conventionally, SCID can be classified as T&#x2212;B+ and T&#x2212;B&#x2212; SCID with further subdivision based on the presence or absence of NK cells. However, the presentation is not always classic, and the presence or absence of NK cells may be misleading. Therefore, a phenotype describing NK cells no longer forms a part of the classification system of the International Union of Immunological Societies [<xref ref-type="bibr" rid="CR47">47</xref>]. It has become clear that clinical presentation has wide phenotype variability with considerable immunological variation [<xref ref-type="bibr" rid="CR43">43</xref>]. These aspects can impede the diagnosis of SCID. In this review, we address the immunological and clinical spectrum of SCID and provide some clues and tools for diagnosing SCID.</p>
    </sec>
    <sec id="Sec2">
      <title>Clinical presentations of SCID</title>
      <sec id="Sec3">
        <title>Classical SCID</title>
        <p>A family history of unusual or fatal infective complications or unexplained infant death is important, particularly in consanguineous families; a history of affected male relatives suggests common gamma chain-deficient SCID. Affected infants generally appear well at birth, but within the first few months of life, demonstrate failure to clear infections and present with persistent respiratory tract or gastrointestinal infections, failure to thrive and, sometimes, apparent food intolerance (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR20">20</xref>]. Persistent respiratory tract infection is common, with failure to clear viruses accompanying persistent bronchiolitic-like signs. Insidiously progressive respiratory disease with radiological evidence of interstitial pneumonitis and hyperinflation suggests <italic>Pneumocystis jiroveci</italic> infection, which may be a co-pathogen with respiratory viruses (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR4">4</xref>]. Persistent viral diarrhoea with failure to thrive is an important sign. Although patients with SCID are often initially well and growing normally, they fall away from the growth centile after a few months when infection occurs because of intestinal villous atrophy, leading to malabsorption, which in severe cases results in malnutrition.
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Presenting features of classical and atypical severe combined immunodeficiency and Omenn syndrome</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Classical SCID</th><th>Omenn syndrome</th><th>Atypical SCID</th></tr></thead><tbody><tr><td>Present in infancy</td><td>Present in infancy</td><td>Present &gt;12&#xA0;months of age</td></tr><tr><td>Persistent viral respiratory +/&#x2212; gastrointestinal infection</td><td>Erythroderma</td><td>Recurrent, severe, prolonged viral infection</td></tr><tr><td><italic>Pneumocystis jiroveci</italic> pneumonitis</td><td>Alopecia</td><td>bronchiectasis</td></tr><tr><td>Disseminated BCG infection</td><td>Hepatosplenomegaly</td><td>Autoimmune cytopenias</td></tr><tr><td>Failure to thrive</td><td>Massive lymphadenopathy</td><td>Failure to thrive</td></tr><tr><td>Superficial candidiasis</td><td>Inflammatory pneumonitis/enteritis</td><td>Granulomatous cutaneous lesions</td></tr><tr><td>Maternofoetal graft versus host disease</td><td>Raised IgE</td><td>EBV-associated lymphoproliferation</td></tr><tr><td>Absent lymphoid tissue</td><td>Eosinophilia</td><td>Partial or restricted antigen-specific antibody responses</td></tr><tr><td>Absent immunoglobulins</td><td>Lymphocytosis</td><td>Lymphopenia</td></tr><tr><td>Absent T lymphocytes</td><td/><td/></tr></tbody></table></table-wrap><fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Chest radiograph from a 5-month-old infant with severe combined immunodeficiency showing bilateral patchy shadowing secondary to interstitial pnuemonitis due to infection with respiratory syncytial virus and <italic>Pneumocystis jiroveci</italic>. There is hyperinflation of the lungs, and the midline pleural borders of the upper lobes are visible because the thymic shadow is absent (courtesy of The Paediatric Immunology Unit, Great North Children&#x2019;s Hospital, Newcastle upon Tyne)</p></caption><graphic xlink:href="431_2011_1452_Fig1_HTML" id="MO1"/></fig></p>
        <p>Bacterial infections are less common in part because of the presence of maternal IgG in early infancy. However, prolonged otitis media and invasive bacterial infections, such as staphylococcal or pseudomonas septicaemia and pneumonia, may occur, which may respond poorly to appropriate treatment. However, patients with associated agranulocytosis, such as those with reticular dysgenesis due to adenylate kinase 2 (AK2) deficiency, generally present in the first few days of life with omphalitis or invasive bacterial sepsis [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
        <p>Severe invasive fungal infection is rare, but often fatal. Extensive persistent superficial candidiasis is more common. Disseminated BCGosis occasionally may be the presenting feature in immunised infants. Skin lesions demonstrate acid fast bacilli on histological analysis. A mild reticular skin rash, which may be thickened and lichenoid, with or without slightly deranged liver function tests may be seen in maternofoetal graft versus host disease. As SCID infants lack functional T cells, they cannot reject foreign lymphocytes acquired from the mother in utero, and so the skin is infiltrated by abnormal maternal T lymphocyte clones [<xref ref-type="bibr" rid="CR41">41</xref>]. A similar clinical picture may occur in patients who have received an unirradiated blood transfusion, due to viable donor lymphocytes in the red cell donation, although in these cases, the rash is more severe and lymphadenopathy and hepatosplenomegaly may be present.</p>
        <p>Examination usually reveals a wasted child who has dropped through the weight centiles&#x2014;head circumference is usually preserved. There may be abdominal distension and muscle wasting due to malabsorption and malnutrition. Respiratory signs may include tachypnoea, nasal flaring, subcostal and intercostal recession, with widespread crepitations and rales, and cyanosis. There may be evidence of oral or perineal candidiasis and other superficial infections. There is no clinically detectable lymphoid tissue, although detecting this in young infants is not easy because lymph nodes and tonsils in normal infants are often very small. There may be hepatomegaly, with or without splenomegaly, particularly when disseminated Bacille Calmette&#x2013;Guerin (BCG) infection is present. Rare presentations include Hodgkin-like polymorphous lymphoproliferative disorder, with rapidly growing extranodal tumours [<xref ref-type="bibr" rid="CR57">57</xref>]. Very rarely, erythrophagocytosis has been described, in association with maternal T lymphocyte engraftment.</p>
      </sec>
      <sec id="Sec4">
        <title>Omenn syndrome</title>
        <p>Omenn syndrome is characterised by a generalised thickened erythematous rash, often with scaling and erythematous exfoliating, protein-losing erythroderma, developing a &#x201C;leathery&#x201D; consistency (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). Hair, including eyebrows and eyelashes, is usually lost as the rash evolves. The rash may be present at birth or evolve over the first few weeks of life. There is an associated lymphadenopathy, particularly of the axillary and inguinal nodes. Hepatosplenomegaly is a frequent finding. There are raised serum IgE levels with a marked eosinophilia and combined immunodeficiency [<xref ref-type="bibr" rid="CR71">71</xref>]. Children usually suffer from diarrhoea, failure to thrive and persistent infection as seen in other forms of SCID&#x2014;staphylococcal or pseudomonas skin infection are particularly common. Affected infants are often miserable because of the high levels of circulating inflammatory cytokines. Pneumonitis and enteritis may be predominantly inflammatory rather than infective. The clinical picture may resemble SCID with maternofoetal engraftment; molecular genetic studies to identify the origin of the dermal infiltrative T lymphocytes can differentiate the two disorders [<xref ref-type="bibr" rid="CR2">2</xref>]. Originally described in patients with mutations in recombinase activation genes (RAG) 1 and 2, mutations in a number of different genes have subsequently been described, including artemis, IL7Ra, RMRP, 22q11 deletion, CHD7, DNA ligase IV (LIG4), adenosine deaminase (ADA) and interleukin 2 receptor, gamma (IL2RG) [<xref ref-type="bibr" rid="CR71">71</xref>].
<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>A newborn infant with Omenn&#x2019;s syndrome due to a mutation in the RAG 1 gene. Note the confluent erythematous exfoliating, thickened rash with a &#x201C;leathery&#x201D; consistency and loss of hair and eyebrows (courtesy of The Paediatric Immunology Unit, Great North Children&#x2019;s Hospital, Newcastle upon Tyne)</p></caption><graphic xlink:href="431_2011_1452_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
      <sec id="Sec5">
        <title>Atypical SCID</title>
        <p>Patients may present with atypical forms of SCID or Omenn syndrome. Previously described as profound combined immunodeficiency, these patients usually survive beyond 12&#xA0;months of age. Increasingly, hypomorphic mutations in genes normally associated with classical SCID are identified, thus retaining some protein function. Alternative mechanisms of demonstrating partial immunity include spontaneous gene reversion in early lymphoid progenitors [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. Such patients present with severe, prolonged infection, which may slowly resolve. Partial antibody responses can be demonstrated to restricted antigens. Other presentations include autoimmune manifestations, particularly with autoimmune cytopenias, and EBV-driven lymphoproliferative tumours. Rarely, cutaneous granulomatous lesions have been described [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. It is important to consider atypical SCID presentations in children presenting beyond the first year of life so that appropriate antimicrobial treatment can be commenced and the patient considered for curative therapy (vide infra).</p>
      </sec>
      <sec id="Sec6">
        <title>Other forms of SCID</title>
        <p>In addition to SCID caused by developmental defects, SCID can also be caused by mutations affecting lymphocyte survival, as seen in patients with reticular dysgenesis due to mutations in AK2 [<xref ref-type="bibr" rid="CR48">48</xref>] and in the enzyme deficiencies ADA and purine nucleoside phosphorylase (PNP), involved in nucleotide metabolism and salvage [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. As a result of the deficiency, toxic metabolites are formed, to which lymphocytes are exquisitely sensitive. Consequently, ADA and PNP deficiencies usually lead to profound lymphopenia [<xref ref-type="bibr" rid="CR54">54</xref>]. Finally, several deficiencies have been described that can give rise to a clinical phenotype of SCID, but only affect a subset of T cells, e.g. MHC class II deficiency, ZAP 70 kinase deficiency [<xref ref-type="bibr" rid="CR47">47</xref>] ([<xref ref-type="bibr" rid="CR62">62</xref>] #1755). Additionally, defects in CD154 (CD40 ligand) and CD40 may present in infancy with <italic>P. jiroveci</italic> pneumonia. These types of SCID will not be further discussed in this review.</p>
      </sec>
    </sec>
    <sec id="Sec7">
      <title>Stepwise diagnostics for SCID</title>
      <sec id="Sec8">
        <title>Flow cytometric immunophenotyping of peripheral blood</title>
        <p>The first step in the diagnostic process in a patient presenting with features consistent with SCID is ruling out HIV infection [<xref ref-type="bibr" rid="CR17">17</xref>]. When HIV has been excluded, a blood smear differential may demonstrate lymphocytopenia, which is suggestive of SCID [<xref ref-type="bibr" rid="CR28">28</xref>]. It should be noted, however, that a normal lymphocyte count on the differential white cell count does not exclude SCID because the absolute number of lymphocytes may be normal, but lymphocyte subsets may be severely reduced or absent. Therefore, flow cytometric immunophenotyping of lymphocyte subsets in peripheral blood is an important screening assay. In classical SCID, the various types can easily be discriminated (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3a</xref>) with a straightforward analysis of B, T and NK cells. For correct interpretation, reference values of age-matched controls should be used [<xref ref-type="bibr" rid="CR13">13</xref>].
<fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>Flow cytometric analysis of peripheral blood and bone marrow of SCID patients. <bold>a</bold> Flow cytometric analysis of lymphocyte subsets in peripheral blood of SCID patients can be used for definition of the type of SCID and guides molecular diagnostics. <bold>b</bold> For B&#x2212; SCID patients, flow cytometric analysis of the bone marrow precursor B cell compartment delineates the precursor B cell differentiation block, which can be helpful in candidate gene selection</p></caption><graphic xlink:href="431_2011_1452_Fig3_HTML" id="MO3"/></fig></p>
        <p>Interpretation of results is more complicated in Omenn syndrome or atypical SCID. These patients present with high numbers of oligoclonal T cells [<xref ref-type="bibr" rid="CR14">14</xref>], the presence of which may be misleading, and so detailed analysis of T cells in patients clinically suspected for typical or atypical SCID is of utmost importance [<xref ref-type="bibr" rid="CR71">71</xref>].</p>
      </sec>
      <sec id="Sec9">
        <title>Gene defects and disease mechanisms in T&#x2212;B+ SCID</title>
        <p>T&#x2212;B+ SCID is caused by mutations in cytokine-mediated signalling. The majority of patients have X-linked SCID caused by mutations in the <italic>IL2RG</italic> gene encoding the common &#x3B3; chain (&#x3B3;c). The &#x3B3;c chain is shared by the IL2, IL4, IL7, IL9, IL15 and IL21 cytokine receptors [<xref ref-type="bibr" rid="CR31">31</xref>]. Cytokines mediate oligomerization of the &#x3B3;c chain with the appropriate cytokine receptor chain, which leads to Janus kinase 1 (JAK1) and Janus kinase 3 (JAK3) activation and phosphorylation of critical tyrosine residues in the receptor chains (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>) [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. JAK1 and JAK3 phosphorylate each other and phosphorylate STAT5. Upon phosphorylation, STAT5 dimerizes and translocates to the nucleus where it activates multiple genes [<xref ref-type="bibr" rid="CR37">37</xref>]. Autosomal recessive forms of T&#x2212;B+ SCID are less frequent and have been shown to be caused by mutations in the <italic>JAK3</italic> or <italic>IL7RA</italic> genes [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Mutations in the <italic>IL7RA</italic> gene abrogate T cell development, but do not interfere with NK cell development.</p>
        <p>A separate category of T&#x2212;B+ SCID patients have mutations in one of the four CD3 genes <italic>(CD3G</italic>, <italic>CD3D</italic>, <italic>CD3E</italic> and <italic>CD3Z</italic>) [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. The CD3 complex is composed of one CD3&#x3B3;, CD3&#x3B4; and CD3&#x3B5; chain and two CD3&#x3B6; chains (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4b</xref>). The absence of one of the CD3 chains inhibits formation of the CD3 complex and consequently expression and signalling via (pre)T cell receptors.
<fig id="Fig4"><label>Fig.&#xA0;4</label><caption><p><bold>a</bold> &#x3B3;c/JAK3 signalling pathway (adapted from Gaspar et al. [<xref ref-type="bibr" rid="CR23">23</xref>]). <bold>b</bold> T cell receptor with CD3 signalling complex</p></caption><graphic xlink:href="431_2011_1452_Fig4_HTML" id="MO4"/></fig></p>
      </sec>
      <sec id="Sec10">
        <title>Gene defects and disease mechanisms in T&#x2212;B&#x2212; SCID</title>
        <p>Patients with T&#x2212;B&#x2212; SCID generally have a defect in V(D)J recombination [<xref ref-type="bibr" rid="CR15">15</xref>]. This process takes place in developing B and T cells and is responsible for the rearrangement of the immunoglobulin and T cell receptor genes (Fig.&#xA0;<xref rid="Fig5" ref-type="fig">5</xref>). Different steps of V(D)J recombination can be discriminated. In the first step, proteins encoded by the recombination activating genes (RAG1 and RAG2) form a heterodimer and make a single-stranded nick between a coding element (Variable (V), Diversity (D), or Joining (J) gene segment and the recombination signal sequence (RSS) [<xref ref-type="bibr" rid="CR69">69</xref>], resulting in the formation of a hairpin-sealed coding end at the side of the coding element and a blunt signal end at the RSS side (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). In the second phase, which is referred to as the processing phase, the DNA&#x2013;protein kinas (PK) complex, composed of Ku70, Ku80 and DNA&#x2013;PKcs, binds to the hairpin-sealed coding end and phosphorylates Artemis, which subsequently opens the hairpin. Further processing of the DNA ends takes place, i.e. nucleotide deletions, random non-templated insertions of nucleotides by TdT before the ends, are ligated by LIG4/XRCC4 in conjunction with Cernunnos/XLF. The first phase of V(D)J recombination is lymphoid specific, while the processing and ligation phase are carried out by the ubiquitously expressed components of the non-homologous end-joining pathway (NHEJ) of DNA double-strand breaks [<xref ref-type="bibr" rid="CR70">70</xref>]. If a mutation occurs in one of the NHEJ factors, the patients not only have defective V(D)J recombination but also a general DNA DSB repair defect, which results in increased sensitivity to ionizing radiation. Mutations have been identified in RAG1, RAG2, Artemis and DNA&#x2013;PKcs giving rise to typical and atypical SCID [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Mutations in LIG4 can give either rise to T&#x2212;B&#x2212; SCID or the LIG4 syndrome, which is characterized by microcephaly and growth retardation [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Mutations in XLF (Cernunnos) also give rise to these manifestations [<xref ref-type="bibr" rid="CR9">9</xref>].
<fig id="Fig5"><label>Fig.&#xA0;5</label><caption><p>A schematic representation of the three steps of the V(D)J recombination process and the involved molecules</p></caption><graphic xlink:href="431_2011_1452_Fig5_HTML" id="MO5"/></fig></p>
      </sec>
      <sec id="Sec11">
        <title>Detailed analysis of T cells potentially present in patients suspected for having typical or atypical SCID</title>
        <p>There are several reasons for the presence of T cells in SCID patients. First, T cells can be engrafted transplacentally from the mother. In 50% of B&#x2212; SCID and in 80% of B+ SCID, maternal T cells can be detected [<xref ref-type="bibr" rid="CR41">41</xref>]. These T cells can be present at low frequencies, but can also exceed the upper limit of reference. The immunophenotype of these T cells can be diverse. Most have a mature (CD45RO+) phenotype, but this cannot be regarded as a golden rule. They may have a disturbed CD4/CD8 ratio or aberrant CD3 expression (van der Burg, unpublished observation). To prove that T cells are maternal, they can be analysed by human leukocyte antigen (HLA) typing or the origin determined by XY FISH in case of boys, or short tandem repeat analysis can be performed [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR68">68</xref>].</p>
        <p>Patients with Omenn syndrome have hypomorphic mutations resulting in the presence of T cells that expanded in the periphery [<xref ref-type="bibr" rid="CR72">72</xref>]. These T cells are autologous and generally oligoclonal. The clonality of the T cells can be determined by flow cytometry, e.g. by using a V&#x3B2; analysis kit [<xref ref-type="bibr" rid="CR63">63</xref>]. Molecular clonality assays by heteroduplex analysis or spectratyping are alternative methods which reliably determine whether the T cells present are oligoclonal, polyclonal or oligoclonal in a polyclonal background [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. The latter would be predominantly due to infections.</p>
        <p>A much rarer explanation for the presence of autologous T cells in SCID patients is the occurrence of somatic reversion mutations [<xref ref-type="bibr" rid="CR73">73</xref>]. These reversion mutations have been described in a few X-linked SCID cases, in a single RAG deficiency and in patients with a CD3Z deficiency [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR74">74</xref>]. In these patients, somatic reversion mutation occurred, probably in early T cells, and corrected the genetic defect. If somatic reversion occurs, the T cells have a selective growth advantage and the potential to develop normal function. The mechanism by which this somatic reversion arises is as yet unknown.</p>
        <p>T cells in patients with suspected typical or atypical SCID should always be typed in detail. Analysis of TCR expression can be particularly helpful. In some patients with a partial V(D)J recombination defect, a high frequency of TCR&#x3B3;&#x3B4; T cells is detected [<xref ref-type="bibr" rid="CR19">19</xref>].</p>
      </sec>
      <sec id="Sec12">
        <title>Analysis of protein expression of candidate genes</title>
        <p>In T&#x2212;B+ SCID, analysis of CD132 expression on lymphocytes and measurement of STAT5 phosphorylation upon IL2 stimulations and informative screening tests are advanced [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. If CD132 expression is absent, this is indicative of X-linked SCID, and in virtually all cases without CD132 expression, a mutation is found in the <italic>IL2RG</italic> gene. The same holds true for the analysis of IL7RA expression. This is somewhat more complicated because IL7R&#x3B1; is mainly expressed on T cells, which are typically absent in these patients. Aberrant results in STAT5 phosphorylation [<xref ref-type="bibr" rid="CR75">75</xref>] point toward defects downstream of the &#x3B3;c chain, and if aberrant, sequence analysis of <italic>JAK3</italic> is a logical choice for molecular analysis.</p>
      </sec>
      <sec id="Sec13">
        <title>Flow cytometric analysis of precursor B cell compartment in bone marrow</title>
        <p>In the case of T&#x2212;B&#x2212; SCID, analysis of the precursor B cell compartment in bone marrow can give information whether or not there is an underlying defect in the V(D)J recombination process. A typical SCID patient with a V(D)J recombination defect due to mutations in <italic>RAG1</italic>, <italic>RAG2</italic>, <italic>Artemis</italic> or <italic>DNA&#x2013;PKcs</italic> has a full block in precursor B cell differentiation before the cytoplasmic Ig&#x3BC;-positive pre-B-II cell stage (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3b</xref>) [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. In a hypomorphic mutation, the differentiation block can be incomplete, implying that low frequencies of pre-B-II can be present. Alternatively, an incomplete precursor B cell differentiation block can be due to the type of gene defect. <italic>LIG4</italic> and <italic>XLF</italic> deficiencies give rise to the presence of pre-B-II and immature B cells and even mature B cells in XLF deficiency [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR65">65</xref>].</p>
      </sec>
      <sec id="Sec14">
        <title>Sequence analysis of candidate genes</title>
        <p>Based on the clinical presentation and the immunophenotype, a candidate gene is selected, and the gene is sequenced to identify a mutation [<xref ref-type="bibr" rid="CR66">66</xref>]. The frequency of mutations in T&#x2212;B+ and T&#x2212;B&#x2212; SCID are depicted in Fig.&#xA0;<xref rid="Fig6" ref-type="fig">6</xref>. For some genes, e.g. RAG1, RAG2 and Artemis, in vitro function tests can be used to determine the level of (reduced) enzymatic activity of the mutation [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. In T&#x2212;B&#x2212; SCID patients without a defect in the <italic>RAG1</italic> or <italic>RAG2</italic> gene, it is important to determine whether the patient is sensitive for ionizing radiation and consequently has a defect in the NHEJ pathway using a clonogenic survival assay on fibroblasts cultured from a skin biopsy [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Analysis of the coding joints of immunoglobulin gene rearrangements in bone marrow precursor B cells, in vivo V(D)J recombination studies, is a valuable tool in the diagnostic process of radiosensitive T&#x2212;B&#x2212; SCID patients because it can give a clue which step in the V(D)J recombination assay is affected [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. The latter tests are not routinely done in a diagnostic setting, but can be of importance in more complicated cases.
<fig id="Fig6"><label>Fig.&#xA0;6</label><caption><p>Distribution of B+ SCID (<italic>n</italic>&#x2009;=&#x2009;159 patients) and B&#x2212; SCID (<italic>n</italic>&#x2009;=&#x2009;136 patients) in Europe according to the ESID patient registry 2010 (<ext-link ext-link-type="uri" xlink:href="http://www.esid.org/statistics.php?sub=2">http://www.esid.org/statistics.php?sub=2</ext-link>). ESID, European Society for Immunodeficiencies</p></caption><graphic xlink:href="431_2011_1452_Fig6_HTML" id="MO6"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec15">
      <title>Supportive management</title>
      <p>Infants suspected of having a severe immunodeficiency disorder should be placed in protected isolation, limiting the numbers of persons involved with care; specifically, individuals with respiratory or gastrointestinal symptoms of infection should avoid contact. If the mother is cytomegalovirus (CMV)-negative, breastfeeding should be encouraged&#x2014;otherwise, it should be discontinued to prevent neonatal CMV infection from being transmitted through breast milk. Strict handwashing procedures are critical to prevent infection. Blood products should be CMV-negative and irradiated to avoid the risk of transfusion GVHD [<xref ref-type="bibr" rid="CR61">61</xref>]. Appropriate imaging of chest, abdominal organs and brain should be considered, guided by the clinical features. For those diagnosed later, particular attention needs to be paid to nutritional status and the management of dietary intolerances secondary to infectious or inflammatory gastrointestinal problems. Advice from paediatric gastroenterologists should be sought early, to minimise the impact of the disease on the gut and to institute modular formula milk feeds or parenteral nutrition as appropriate. Respiratory paediatricians should be consulted early to maximise supportive therapy and prevent further lung damage. Imaging to detect focal infiltration is important and may guide subsequent biopsy. Infection should be sought aggressively, and biopsy material may be required to demonstrate infection. Culture of appropriate tissue specimens, including bronchoalveolar lavage fluid, and PCR may be needed to identify infecting pathogens&#x2014;serology is generally unhelpful. Infections should be vigorously treated&#x2014;broad spectrum multi-agent antimicrobial therapy may be required. Co-trimoxazole as prophylaxis against <italic>P. jiroveci</italic> should be given. Antifungal prophylaxis should also be used, and antiviral prophylaxis with aciclovir is used in patients with a previous herpes simplex infection. Supporting the emotional needs of the family is also very important.</p>
      <sec id="Sec16">
        <title>Curative therapy</title>
        <p>Hematopoeitic stem cell transplantation (HSCT) is the treatment of choice for patients with SCID. If HSCT with conditioning chemotherapy is embarked upon, isolation in facilities with positive-pressure-filtered air supply is necessary, mainly to reduce the risk of aspergillosis and droplet-borne viral infections. European data regarding outcome of HSCT for SCID Patient data are collected in the Stem Cell Transplantation for Immunodeficiencies in Europe registry, giving data on almost 700 patients, and have recently been published [<xref ref-type="bibr" rid="CR24">24</xref>]. A broad repertoire of stem cell sources are used, including stem cells from marrow, mobilised peripheral blood stem cells or those harvested from umbilical cord blood. Best results are obtained using HLA-matched sibling donors, with survival of around 90% in the best circumstances. The molecular defect has a bearing on outcome, with B&#x2212; SCID patients having an overall worse outcome than B+ forms of SCID [<xref ref-type="bibr" rid="CR42">42</xref>]. The outcome is better in the absence of infection, arguing for the early identification of patients through neonatal screening programmes [<xref ref-type="bibr" rid="CR8">8</xref>]. New chemotherapy conditioning regimens are increasingly utilised, with improved outcome. A successful procedure is generally curative, with patients leading normal lives off medication, but few long-term studies have demonstrated long-term sequelae for some patients [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. Particular problems relate to ongoing thymopoiesis, with failure leading to T lymphocyte senescence in the long term [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Long-term immunoglobulin therapy is necessary for some B lymphocyte dysfunction or failure of donor engraftment. Chemotherapy may lead to infertility. Hypothyroidism, secondary to chemotherapy, affects about 10% of patients. Some sequelae relate to the specific genetic defect, for instance, human papillomavirus-associated warts in IL2RG/JAK3 SCID [<xref ref-type="bibr" rid="CR33">33</xref>] and neurodevelopmental disorders in ADA deficiency [<xref ref-type="bibr" rid="CR53">53</xref>].</p>
        <p>For ADA deficiency, enzyme replacement therapy with polyethelyne-glycosylated ADA is an alternative treatment [<xref ref-type="bibr" rid="CR29">29</xref>]. Treatment is required lifelong, is expensive and results in only partial immune reconstitution. Sequalae include the development of autoimmunity, but in the short term, it may allow some immune reconstitution and clearance of infection before proceeding to definitive therapy.</p>
        <p>Gene therapy has been used for ADA- and IL2RG-deficient SCID [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Advantages include removal of the necessity for chemotherapy conditioning and available treatment despite lack of a matched donor. Earlier ADA trials were only partially successful, and the majority of patients required ongoing PEG-ADA therapy. More recently, the procedure has been more successful, although low doses of chemotherapy give the best results [<xref ref-type="bibr" rid="CR22">22</xref>]. Some patients have an ongoing requirement for immunoglobulin replacement. XL-SCID gene therapy does not require chemotherapy and has led to complete immune reconstitution, but insertion of the retroviral vector close to oncogenes has led to the development of lymphoproliferation in some patients [<xref ref-type="bibr" rid="CR27">27</xref>]. Development of new, probably safer, vectors and directed insertion of the mutated gene away from oncogenes promise improved outcome, and clinical trials are ongoing [<xref ref-type="bibr" rid="CR51">51</xref>]. Treatment of other forms of SCID is at a pre-clinical phase.</p>
      </sec>
    </sec>
    <sec id="Sec17">
      <title>Concluding remarks</title>
      <p>SCID is one of the most severe forms of primary immunodeficiency and is a paediatric emergency, which is life-threatening if recognized too late. Therefore, early diagnosis and good clinical management are crucial. The clinical and immunological spectrum of SCID is broader than initially described, so (atypical) SCID should be considered as a potential diagnosis more often. Improved supportive care, detection of infection by molecular means and less toxic chemotherapy conditioning regimens have significantly improved survival, and patients should be referred urgently to centres specializing in the diagnosis and treatment of such patients to optimize outcome.</p>
      <sec id="Sec18">
        <title>Learning points</title>
        <p>
          <list list-type="bullet">
            <list-item>
              <p>&#x25AA; SCID is one of the most severe forms of PID and is a life-threatening paediatric emergency.</p>
            </list-item>
            <list-item>
              <p>&#x25AA; The molecular basis of most forms of SCID is now recognized.</p>
            </list-item>
            <list-item>
              <p>&#x25AA; Early careful liaison with the immunology laboratory will enable the most appropriate investigations to be performed.</p>
            </list-item>
            <list-item>
              <p>&#x25AA; Atypical, later presentation of patients with partial gene function is increasingly described.</p>
            </list-item>
            <list-item>
              <p>&#x25AA; Atypical SCID should be considered in patients presenting with unusual, severe or recurrent infections.</p>
            </list-item>
          </list>
        </p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aiuti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cattaneo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Galimberti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Benninghoff</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Cassani</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Callegaro</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Scaramuzza</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Andolfi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mirolo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brigida</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Tabucchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Carlucci</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Eibl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aker</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Slavin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Al-Mousa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Al Ghonaium</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ferster</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Duppenthaler</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Notarangelo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wintergerst</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Buckley</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Bregni</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marktel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Valsecchi</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ciceri</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Miniero</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bordignon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Roncarolo</surname>
              <given-names>MG</given-names>
            </name>
          </person-group>
          <article-title>Gene therapy for immunodeficiency due to adenosine deaminase deficiency</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>360</volume>
          <fpage>447</fpage>
          <lpage>458</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa0805817</pub-id>
          <pub-id pub-id-type="pmid">19179314</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Appleton</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Curtis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wilkes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cant</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Differentiation of materno-fetal GVHD from Omenn&#x2019;s syndrome in pre-BMT patients with severe combined immunodeficiency</article-title>
          <source>Bone Marrow Transplant</source>
          <year>1994</year>
          <volume>14</volume>
          <fpage>157</fpage>
          <lpage>159</lpage>
          <pub-id pub-id-type="pmid">7951106</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Benke</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Dittmar</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Purine dysfunction in cells from patients with adenosine deaminase deficiency</article-title>
          <source>Pediatr Res</source>
          <year>1976</year>
          <volume>10</volume>
          <fpage>642</fpage>
          <lpage>646</lpage>
          <pub-id pub-id-type="pmid">132630</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berrington</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Flood</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Abinun</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Galloway</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cant</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Unsuspected <italic>Pneumocystis carinii</italic> pneumonia at presentation of severe primary immunodeficiency</article-title>
          <source>Arch Dis Child</source>
          <year>2000</year>
          <volume>82</volume>
          <fpage>144</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="doi">10.1136/adc.82.2.144</pub-id>
          <pub-id pub-id-type="pmid">10648370</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bertrand</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Casanova</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Friedrich</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Reticular dysgenesis: HLA non-identical bone marrow transplants in a series of 10 patients</article-title>
          <source>Bone Marrow Transplant</source>
          <year>2002</year>
          <volume>29</volume>
          <fpage>759</fpage>
          <lpage>762</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.bmt.1703531</pub-id>
          <pub-id pub-id-type="pmid">12040473</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blaese</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Culver</surname>
              <given-names>KW</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Fleisher</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Clerici</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Shearer</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chiang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tolstoshev</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Greenblatt</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Klein</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mullen</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Ramsey</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Muul</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>WF</given-names>
            </name>
          </person-group>
          <article-title>T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4&#xA0;years</article-title>
          <source>Science</source>
          <year>1995</year>
          <volume>270</volume>
          <fpage>475</fpage>
          <lpage>480</lpage>
          <pub-id pub-id-type="doi">10.1126/science.270.5235.475</pub-id>
          <pub-id pub-id-type="pmid">7570001</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borghans</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Bredius</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Hazenberg</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Roelofs</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Jol-van der Zijde</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Heidt</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Otto</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Kuijpers</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Fibbe</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Vossen</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Miedema</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tol</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Early determinants of long-term <italic>T</italic>-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency</article-title>
          <source>Blood</source>
          <year>2006</year>
          <volume>108</volume>
          <fpage>763</fpage>
          <lpage>769</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2006-01-009241</pub-id>
          <pub-id pub-id-type="pmid">16822903</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Xu-Bayford</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Allwood</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Slatter</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cant</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Veys</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gennery</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Gaspar</surname>
              <given-names>HB</given-names>
            </name>
          </person-group>
          <article-title>Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>117</volume>
          <issue>11</issue>
          <fpage>3243</fpage>
          <lpage>3246</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2010-08-300384</pub-id>
          <pub-id pub-id-type="pmid">21273302</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buck</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Malivert</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chasseval</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Barraud</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fondaneche</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Sanal</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Plebani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stephan</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Hufnagel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Deist</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Durandy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Villartay</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Revy</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly</article-title>
          <source>Cell</source>
          <year>2006</year>
          <volume>124</volume>
          <fpage>287</fpage>
          <lpage>299</lpage>
          <pub-id pub-id-type="doi">10.1016/j.cell.2005.12.030</pub-id>
          <pub-id pub-id-type="pmid">16439204</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cavazzana-Calvo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Carlier</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Deist</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Morillon</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Taupin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gautier</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Radford-Weiss</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Caillat-Zucman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Neven</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Blanche</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cheynier</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hacein-Bey-Abina</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Long-term <italic>T</italic>-cell reconstitution after hematopoietic stem-cell transplantation in primary <italic>T</italic>-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype</article-title>
          <source>Blood</source>
          <year>2007</year>
          <volume>109</volume>
          <fpage>4575</fpage>
          <lpage>4581</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2006-07-029090</pub-id>
          <pub-id pub-id-type="pmid">17272510</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cavazzana-Calvo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hacein-Bey</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Saint</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Yvon</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nusbaum</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Selz</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hue</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Certain</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Casanova</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Bousso</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Deist</surname>
              <given-names>FL</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease</article-title>
          <source>Science</source>
          <year>2000</year>
          <volume>288</volume>
          <fpage>669</fpage>
          <lpage>672</lpage>
          <pub-id pub-id-type="doi">10.1126/science.288.5466.669</pub-id>
          <pub-id pub-id-type="pmid">10784449</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cohen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Doyle</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>DW</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Ammann</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase</article-title>
          <source>N Engl J Med</source>
          <year>1976</year>
          <volume>295</volume>
          <fpage>1449</fpage>
          <lpage>1454</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM197612232952603</pub-id>
          <pub-id pub-id-type="pmid">825775</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Comans-Bitter</surname>
              <given-names>WM</given-names>
            </name>
            <name>
              <surname>Groot</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Beemd</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Neijens</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Hop</surname>
              <given-names>WCJ</given-names>
            </name>
            <name>
              <surname>Groeneveld</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hooijkaas</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dongen</surname>
              <given-names>JJM</given-names>
            </name>
          </person-group>
          <article-title>Immunophenotyping of blood lymphocytes in childhood</article-title>
          <source>J Pediatr</source>
          <year>1997</year>
          <volume>130</volume>
          <fpage>388</fpage>
          <lpage>393</lpage>
          <pub-id pub-id-type="doi">10.1016/S0022-3476(97)70200-2</pub-id>
          <pub-id pub-id-type="pmid">9063413</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saint-Basile</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Deist</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Villartay</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Cerf-Bensussan</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Journet</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Brousse</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Griscelli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Restricted heterogeneity of T lymphocytes in combined immunodeficiency with hypereosinophilia (Omenn&#x2019;s syndrome)</article-title>
          <source>J Clin Invest</source>
          <year>1991</year>
          <volume>87</volume>
          <fpage>1352</fpage>
          <lpage>1359</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI115139</pub-id>
          <pub-id pub-id-type="pmid">2010548</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Villartay</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>V(D)J recombination deficiencies</article-title>
          <source>Adv Exp Med Biol</source>
          <year>2009</year>
          <volume>650</volume>
          <fpage>46</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="doi">10.1007/978-1-4419-0296-2_4</pub-id>
          <pub-id pub-id-type="pmid">19731800</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Villartay</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Al-Mousa</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dupont</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dechanet-Merville</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Coumau-Gatbois</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gougeon</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Lemainque</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Eidenschenk</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jouanguy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Abel</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Casanova</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Deist</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection</article-title>
          <source>J Clin Invest</source>
          <year>2005</year>
          <volume>115</volume>
          <fpage>3291</fpage>
          <lpage>3299</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI25178</pub-id>
          <pub-id pub-id-type="pmid">16276422</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vries</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists</article-title>
          <source>Clin Exp Immunol</source>
          <year>2006</year>
          <volume>145</volume>
          <fpage>204</fpage>
          <lpage>214</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2249.2006.03138.x</pub-id>
          <pub-id pub-id-type="pmid">16879238</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vries</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Driessen</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Educational paper: primary immunodeficiencies in children: a diagnostic challenge</article-title>
          <source>Eur J Pediatr</source>
          <year>2011</year>
          <volume>170</volume>
          <fpage>169</fpage>
          <lpage>177</lpage>
          <pub-id pub-id-type="doi">10.1007/s00431-010-1358-5</pub-id>
          <pub-id pub-id-type="pmid">21170549</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ehl</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Enders</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Duffner</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Pannicke</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Kuhr</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mascart</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schmitt-Graeff</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Niemeyer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fisch</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>A variant of SCID with specific immune responses and predominance of gamma delta T cells</article-title>
          <source>J Clin Invest</source>
          <year>2005</year>
          <volume>115</volume>
          <fpage>3140</fpage>
          <lpage>3148</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI25221</pub-id>
          <pub-id pub-id-type="pmid">16211094</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Severe combined immunodeficiencies (SCID)</article-title>
          <source>Clin Exp Immunol</source>
          <year>2000</year>
          <volume>122</volume>
          <fpage>143</fpage>
          <lpage>149</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2249.2000.01359.x</pub-id>
          <pub-id pub-id-type="pmid">11091267</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Saint</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Deist</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>CD3 deficiencies</article-title>
          <source>Curr Opin Allergy Clin Immunol</source>
          <year>2005</year>
          <volume>5</volume>
          <fpage>491</fpage>
          <lpage>495</lpage>
          <pub-id pub-id-type="doi">10.1097/01.all.0000191886.12645.79</pub-id>
          <pub-id pub-id-type="pmid">16264327</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gaspar</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Bjorkegren</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Parsley</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gilmour</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sinclair</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Giannakopoulos</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fairbanks</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Gaspar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Henderson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Xu-Bayford</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Veys</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Kinnon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Thrasher</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning</article-title>
          <source>Mol Ther</source>
          <year>2006</year>
          <volume>14</volume>
          <fpage>505</fpage>
          <lpage>513</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ymthe.2006.06.007</pub-id>
          <pub-id pub-id-type="pmid">16905365</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gaspar</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Gilmour</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title>Severe combined immunodeficiency&#x2014;molecular pathogenesis and diagnosis</article-title>
          <source>Arch Dis Child</source>
          <year>2001</year>
          <volume>84</volume>
          <fpage>169</fpage>
          <lpage>173</lpage>
          <pub-id pub-id-type="doi">10.1136/adc.84.2.169</pub-id>
          <pub-id pub-id-type="pmid">11159300</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gennery</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Slatter</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Grandin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Taupin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cant</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Veys</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Amrolia</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Gaspar</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Friedrich</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hoenig</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Notarangelo</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Mazzolari</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Porta</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bredius</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Lankester</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Wulffraat</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Seger</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gungor</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fasth</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sedlacek</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Neven</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Blanche</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cavazzana-Calvo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Landais</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better?</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2010</year>
          <volume>126</volume>
          <issue>602&#x2013;610</issue>
          <fpage>e601</fpage>
          <lpage>e611</lpage>
        </mixed-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gilmour</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Cranston</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Loughlin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gwyther</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lester</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Espanol</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hernandez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Savoldi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Abinun</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kinnon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gaspar</surname>
              <given-names>HB</given-names>
            </name>
          </person-group>
          <article-title>Rapid protein-based assays for the diagnosis of T-B+ severe combined immunodeficiency</article-title>
          <source>Br J Haematol</source>
          <year>2001</year>
          <volume>112</volume>
          <fpage>671</fpage>
          <lpage>676</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2141.2001.02578.x</pub-id>
          <pub-id pub-id-type="pmid">11260071</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Girard</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Kysela</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Harer</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Doherty</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Jeggo</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Analysis of DNA ligase IV mutations found in LIG4 syndrome patients: the impact of two linked polymorphisms</article-title>
          <source>Hum Mol Genet</source>
          <year>2004</year>
          <volume>13</volume>
          <fpage>2369</fpage>
          <lpage>2376</lpage>
          <pub-id pub-id-type="doi">10.1093/hmg/ddh274</pub-id>
          <pub-id pub-id-type="pmid">15333585</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hacein-Bey-Abina</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kalle</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McCormack</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Wulffraat</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Leboulch</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Osborne</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Pawliuk</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Morillon</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sorensen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Forster</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>JI</given-names>
            </name>
            <name>
              <surname>Saint</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Alexander</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Wintergerst</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Frebourg</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Aurias</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stoppa-Lyonnet</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Romana</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Radford-Weiss</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gross</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Valensi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Delabesse</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Macintyre</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sigaux</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Soulier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Leiva</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Wissler</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Prinz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rabbitts</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Deist</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cavazzana-Calvo</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1</article-title>
          <source>Science</source>
          <year>2003</year>
          <volume>302</volume>
          <fpage>415</fpage>
          <lpage>419</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1088547</pub-id>
          <pub-id pub-id-type="pmid">14564000</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hague</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Rassam</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cant</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Early diagnosis of severe combined immunodeficiency syndrome</article-title>
          <source>Arch Dis Child</source>
          <year>1994</year>
          <volume>70</volume>
          <fpage>260</fpage>
          <lpage>263</lpage>
          <pub-id pub-id-type="doi">10.1136/adc.70.4.260</pub-id>
          <pub-id pub-id-type="pmid">8185357</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hershfield</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
          <article-title>Enzyme replacement therapy of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase (PEG-ADA)</article-title>
          <source>Immunodeficiency</source>
          <year>1993</year>
          <volume>4</volume>
          <fpage>93</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="pmid">8167743</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <mixed-citation publication-type="other">IJspeert H, Lankester AC, Van den Berg JM, Wiegant W, Van Zelm MC, Weemaes CMR, Warris A, Pan-Hammarstr&#xF6;m Q, Pastink A, Van Tol MJD, Van Dongen JJM, Van Gent DC, Van der Burg M (2011) Artemis splice defects cause atypical SCID and can be restored in vitro by an antisense oligonucleotide. Genes Immun (in press)</mixed-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kovanen</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Leonard</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
          <article-title>Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways</article-title>
          <source>Immunol Rev</source>
          <year>2004</year>
          <volume>202</volume>
          <fpage>67</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="doi">10.1111/j.0105-2896.2004.00203.x</pub-id>
          <pub-id pub-id-type="pmid">15546386</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumaki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Villa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Asada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kawai</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ohashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Takahashi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hakozaki</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Nitanai</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Minegishi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tsuchiya</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Identification of anti-herpes simplex virus antibody-producing B cells in a patient with an atypical RAG1 immunodeficiency</article-title>
          <source>Blood</source>
          <year>2001</year>
          <volume>98</volume>
          <fpage>1464</fpage>
          <lpage>1468</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.V98.5.1464</pub-id>
          <pub-id pub-id-type="pmid">11520796</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laffort</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Deist</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Favre</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Caillat-Zucman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Radford-Weiss</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Debre</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fraitag</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Blanche</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cavazzana-Calvo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saint</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Villartay</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Giliani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Orth</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Casanova</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Bodemer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency</article-title>
          <source>Lancet</source>
          <year>2004</year>
          <volume>363</volume>
          <fpage>2051</fpage>
          <lpage>2054</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(04)16457-X</pub-id>
          <pub-id pub-id-type="pmid">15207958</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Langerak</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Szczepanski</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Burg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wolvers-Tettero</surname>
              <given-names>ILM</given-names>
            </name>
            <name>
              <surname>Dongen</surname>
              <given-names>JJM</given-names>
            </name>
          </person-group>
          <article-title>Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations</article-title>
          <source>Leukemia</source>
          <year>1997</year>
          <volume>11</volume>
          <fpage>2192</fpage>
          <lpage>2199</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.leu.2400887</pub-id>
          <pub-id pub-id-type="pmid">9447840</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Langerak</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Beemd</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wolvers-Tettero</surname>
              <given-names>IL</given-names>
            </name>
            <name>
              <surname>Boor</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Lochem</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Hooijkaas</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dongen</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta <italic>T</italic>-cell proliferations</article-title>
          <source>Blood</source>
          <year>2001</year>
          <volume>98</volume>
          <fpage>165</fpage>
          <lpage>173</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.V98.1.165</pub-id>
          <pub-id pub-id-type="pmid">11418476</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leonard</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>JX</given-names>
            </name>
          </person-group>
          <article-title>Cytokine receptor signaling pathways</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2000</year>
          <volume>105</volume>
          <fpage>877</fpage>
          <lpage>888</lpage>
          <pub-id pub-id-type="doi">10.1067/mai.2000.106899</pub-id>
          <pub-id pub-id-type="pmid">10808165</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lin</surname>
              <given-names>JX</given-names>
            </name>
            <name>
              <surname>Leonard</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
          <article-title>The role of Stat5a and Stat5b in signaling by IL-2 family cytokines</article-title>
          <source>Oncogene</source>
          <year>2000</year>
          <volume>19</volume>
          <fpage>2566</fpage>
          <lpage>2576</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1203523</pub-id>
          <pub-id pub-id-type="pmid">10851055</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Macchi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Villa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giliani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sacco</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Frattini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Porta</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ugazio</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Johnston</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Candotti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>O&#x2019;Shea</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Vezzoni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Notarangelo</surname>
              <given-names>LD</given-names>
            </name>
          </person-group>
          <article-title>Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)</article-title>
          <source>Nature</source>
          <year>1995</year>
          <volume>377</volume>
          <fpage>65</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="doi">10.1038/377065a0</pub-id>
          <pub-id pub-id-type="pmid">7659163</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mazzolari</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Martiis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Forino</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lanfranchi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Giliani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Marzollo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Airo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Imberti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Porta</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Notarangelo</surname>
              <given-names>LD</given-names>
            </name>
          </person-group>
          <article-title>Single-center analysis of long-term outcome after hematopoietic cell transplantation in children with congenital severe T cell immunodeficiency</article-title>
          <source>Immunol Res</source>
          <year>2009</year>
          <volume>44</volume>
          <fpage>4</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="doi">10.1007/s12026-008-8022-4</pub-id>
          <pub-id pub-id-type="pmid">18592143</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moshous</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Callebaut</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Chasseval</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Corneo</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Cavazzana-Calvo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Deist</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tezcan</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Sanal</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Bertrand</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Philippe</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Villartay</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency</article-title>
          <source>Cell</source>
          <year>2001</year>
          <volume>105</volume>
          <fpage>177</fpage>
          <lpage>186</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(01)00309-9</pub-id>
          <pub-id pub-id-type="pmid">11336668</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muller</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Ege</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pottharst</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schulz</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Friedrich</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Transplacentally acquired maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients</article-title>
          <source>Blood</source>
          <year>2001</year>
          <volume>98</volume>
          <fpage>1847</fpage>
          <lpage>1851</lpage>
          <pub-id pub-id-type="doi">10.1182/blood.V98.6.1847</pub-id>
          <pub-id pub-id-type="pmid">11535520</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neven</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Leroy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Decaluwe</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Deist</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Picard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Moshous</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mahlaoui</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Debre</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Casanova</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Dal Cortivo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Madec</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Hacein-Bey-Abina</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Saint</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Villartay</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Blanche</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cavazzana-Calvo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>113</volume>
          <fpage>4114</fpage>
          <lpage>4124</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2008-09-177923</pub-id>
          <pub-id pub-id-type="pmid">19168787</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Niehues</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Perez-Becker</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schuetz</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>More than just SCID&#x2014;the phenotypic range of combined immunodeficiencies associated with mutations in the recombinase activating genes (RAG) 1 and 2</article-title>
          <source>Clin Immunol</source>
          <year>2010</year>
          <volume>135</volume>
          <fpage>183</fpage>
          <lpage>192</lpage>
          <pub-id pub-id-type="doi">10.1016/j.clim.2010.01.013</pub-id>
          <pub-id pub-id-type="pmid">20172764</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Noordzij</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Bruin-Versteeg</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Verkaik</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Vossen</surname>
              <given-names>JMJJ</given-names>
            </name>
            <name>
              <surname>Groot</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bernatowska</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Langerak</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Gent</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Dongen</surname>
              <given-names>JJM</given-names>
            </name>
          </person-group>
          <article-title>The immunophenotypic and immunogenotypic <italic>B</italic>-cell differentiation arrest in bone marrow of RAG deficient SCID patients corresponds to residual recombination activities of mutated RAG proteins</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>100</volume>
          <fpage>2145</fpage>
          <lpage>2152</lpage>
          <pub-id pub-id-type="pmid">12200379</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Noordzij</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Verkaik</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Burg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Veelen</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Bruin-Versteeg</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wiegant</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Vossen</surname>
              <given-names>JMJJ</given-names>
            </name>
            <name>
              <surname>Weemaes</surname>
              <given-names>CMR</given-names>
            </name>
            <name>
              <surname>Groot</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zdzienicka</surname>
              <given-names>MZ</given-names>
            </name>
            <name>
              <surname>Gent</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Dongen</surname>
              <given-names>JJM</given-names>
            </name>
          </person-group>
          <article-title>Radiosensitive SCID patients with Artemis gene mutations show a complete <italic>B</italic>-cell differentiation arrest at the pre-B-cell receptor checkpoint in bone marrow</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>101</volume>
          <fpage>1446</fpage>
          <lpage>1452</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2002-01-0187</pub-id>
          <pub-id pub-id-type="pmid">12406895</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Notarangelo</surname>
              <given-names>LD</given-names>
            </name>
          </person-group>
          <article-title>Primary immunodeficiencies</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2010</year>
          <volume>125</volume>
          <fpage>S182</fpage>
          <lpage>S194</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2009.07.053</pub-id>
          <pub-id pub-id-type="pmid">20042228</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Notarangelo</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Geha</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Casanova</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Chapel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Conley</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Cunningham-Rundles</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Etzioni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hammartrom</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Nonoyama</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ochs</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Puck</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Roifman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Seger</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wedgwood</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Primary immunodeficiencies: 2009 update</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2009</year>
          <volume>124</volume>
          <fpage>1161</fpage>
          <lpage>1178</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2009.10.013</pub-id>
          <pub-id pub-id-type="pmid">20004777</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pannicke</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Honig</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hess</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Friesen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Holzmann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rump</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Barth</surname>
              <given-names>TF</given-names>
            </name>
            <name>
              <surname>Rojewski</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Schulz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Boehm</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Friedrich</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Reticular dysgenesis (aleukocytosis) is caused by mutations in the gene encoding mitochondrial adenylate kinase 2</article-title>
          <source>Nat Genet</source>
          <year>2009</year>
          <volume>41</volume>
          <fpage>101</fpage>
          <lpage>105</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.265</pub-id>
          <pub-id pub-id-type="pmid">19043417</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poinsignon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Moshous</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Callebaut</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Chasseval</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Villey</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Villartay</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>The metallo-beta-lactamase/beta-CASP domain of Artemis constitutes the catalytic core for V(D)J recombination</article-title>
          <source>J Exp Med</source>
          <year>2004</year>
          <volume>199</volume>
          <fpage>315</fpage>
          <lpage>321</lpage>
          <pub-id pub-id-type="doi">10.1084/jem.20031142</pub-id>
          <pub-id pub-id-type="pmid">14744996</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Puel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ziegler</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Buckley</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Leonard</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
          <article-title>Defective IL7R expression in T(&#x2212;)B(+)NK(+) severe combined immunodeficiency</article-title>
          <source>Nat Genet</source>
          <year>1998</year>
          <volume>20</volume>
          <fpage>394</fpage>
          <lpage>397</lpage>
          <pub-id pub-id-type="doi">10.1038/3877</pub-id>
          <pub-id pub-id-type="pmid">9843216</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qasim</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Gaspar</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Thrasher</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Progress and prospects: gene therapy for inherited immunodeficiencies</article-title>
          <source>Gene Ther</source>
          <year>2009</year>
          <volume>16</volume>
          <fpage>1285</fpage>
          <lpage>1291</lpage>
          <pub-id pub-id-type="doi">10.1038/gt.2009.127</pub-id>
          <pub-id pub-id-type="pmid">19776764</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rieux-Laucat</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hivroz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mateo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Pellier</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Selz</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Deist</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Inherited and somatic CD3zeta mutations in a patient with <italic>T</italic>-cell deficiency</article-title>
          <source>N Engl J Med</source>
          <year>2006</year>
          <volume>354</volume>
          <fpage>1913</fpage>
          <lpage>1921</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa053750</pub-id>
          <pub-id pub-id-type="pmid">16672702</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rogers</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Lwin</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fairbanks</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gerritsen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gaspar</surname>
              <given-names>HB</given-names>
            </name>
          </person-group>
          <article-title>Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency</article-title>
          <source>J Pediatr</source>
          <year>2001</year>
          <volume>139</volume>
          <fpage>44</fpage>
          <lpage>50</lpage>
          <pub-id pub-id-type="doi">10.1067/mpd.2001.115023</pub-id>
          <pub-id pub-id-type="pmid">11445793</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sauer</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Aiuti</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy</article-title>
          <source>Curr Opin Allergy Clin Immunol</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>496</fpage>
          <lpage>502</lpage>
          <pub-id pub-id-type="doi">10.1097/ACI.0b013e3283327da5</pub-id>
          <pub-id pub-id-type="pmid">19779332</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schuetz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Huck</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gudowius</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Megahed</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Feyen</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Hubner</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Manfras</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pannicke</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Willemze</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Knuchel</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gobel</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Schulz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Borkhardt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Friedrich</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Niehues</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>An immunodeficiency disease with RAG mutations and granulomas</article-title>
          <source>N Engl J Med</source>
          <year>2008</year>
          <volume>358</volume>
          <fpage>2030</fpage>
          <lpage>2038</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa073966</pub-id>
          <pub-id pub-id-type="pmid">18463379</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwarz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gauss</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Ludwig</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pannicke</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lindner</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Friedrich</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Seger</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Hansen-Hagge</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Desiderio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lieber</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Bartram</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>RAG mutations in human B cell-negative SCID</article-title>
          <source>Science</source>
          <year>1996</year>
          <volume>274</volume>
          <fpage>97</fpage>
          <lpage>99</lpage>
          <pub-id pub-id-type="doi">10.1126/science.274.5284.97</pub-id>
          <pub-id pub-id-type="pmid">8810255</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Slatter</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Angus</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Windebank</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Meaney</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lester</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Norbury</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hambleton</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Abinun</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Flood</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Cant</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Gennery</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Polymorphous lymphoproliferative disorder with Hodgkin-like features in common gamma-chain-deficient severe combined immunodeficiency</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2011</year>
          <volume>127</volume>
          <fpage>533</fpage>
          <lpage>535</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2010.09.036</pub-id>
          <pub-id pub-id-type="pmid">21094519</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Slatter</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Brigham</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dickinson</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Harvey</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Barge</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Jackson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bown</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Flood</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Cant</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Abinun</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gennery</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
          <article-title>Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe <italic>T</italic>-lymphocyte immunodeficiency</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2008</year>
          <volume>121</volume>
          <fpage>361</fpage>
          <lpage>367</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2007.10.035</pub-id>
          <pub-id pub-id-type="pmid">18086494</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Speckmann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pannicke</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Wiech</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fisch</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Friedrich</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Niehues</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gilmour</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Buiting</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Schlesier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Eibel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Rohr</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Superti-Furga</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gross-Wieltsch</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Ehl</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Clinical and immunologic consequences of a somatic reversion in a patient with X-linked severe combined immunodeficiency</article-title>
          <source>Blood</source>
          <year>2008</year>
          <volume>112</volume>
          <fpage>4090</fpage>
          <lpage>4097</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2008-04-153361</pub-id>
          <pub-id pub-id-type="pmid">18728247</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stephan</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Wahn</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Deist</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Dirksen</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Broker</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Muller-Fleckenstein</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Horneff</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Schroten</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Saint</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells</article-title>
          <source>N Engl J Med</source>
          <year>1996</year>
          <volume>335</volume>
          <fpage>1563</fpage>
          <lpage>1567</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199611213352104</pub-id>
          <pub-id pub-id-type="pmid">8900089</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Treleaven</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gennery</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Marsh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Norfolk</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Page</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Saran</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Thurston</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force</article-title>
          <source>Br J Haematol</source>
          <year>2011</year>
          <volume>152</volume>
          <fpage>35</fpage>
          <lpage>51</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2010.08444.x</pub-id>
          <pub-id pub-id-type="pmid">21083660</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Turul</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tezcan</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Artac</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bruin-Versteeg</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Barendregt</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Reisli</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Sanal</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Dongen</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Burg</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Clinical heterogeneity can hamper the diagnosis of patients with ZAP70 deficiency</article-title>
          <source>Eur J Pediatr</source>
          <year>2009</year>
          <volume>168</volume>
          <fpage>87</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="doi">10.1007/s00431-008-0718-x</pub-id>
          <pub-id pub-id-type="pmid">18509675</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beemd</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Boor</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Lochem</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Hop</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Langerak</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Wolvers-Tettero</surname>
              <given-names>IL</given-names>
            </name>
            <name>
              <surname>Hooijkaas</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Dongen</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Flow cytometric analysis of the Vbeta repertoire in healthy controls</article-title>
          <source>Cytometry</source>
          <year>2000</year>
          <volume>40</volume>
          <fpage>336</fpage>
          <lpage>345</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0320(20000801)40:4&lt;336::AID-CYTO9&gt;3.0.CO;2-0</pub-id>
          <pub-id pub-id-type="pmid">10918284</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ijspeert</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Verkaik</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Turul</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wiegant</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Morotomi-Yano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mari</surname>
              <given-names>PO</given-names>
            </name>
            <name>
              <surname>Tezcan</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Zdzienicka</surname>
              <given-names>MZ</given-names>
            </name>
            <name>
              <surname>Dongen</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Gent</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
          <article-title>A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining</article-title>
          <source>J Clin Invest</source>
          <year>2009</year>
          <volume>119</volume>
          <fpage>91</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="pmid">19075392</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Veelen</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Verkaik</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Wiegant</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Hartwig</surname>
              <given-names>NG</given-names>
            </name>
            <name>
              <surname>Barendregt</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Brugmans</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Raams</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jaspers</surname>
              <given-names>NG</given-names>
            </name>
            <name>
              <surname>Zdzienicka</surname>
              <given-names>MZ</given-names>
            </name>
            <name>
              <surname>Dongen</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Gent</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
          <article-title>A new type of radiosensitive T-B-NK+ severe combined immunodeficiency caused by a LIG4 mutation</article-title>
          <source>J Clin Invest</source>
          <year>2006</year>
          <volume>116</volume>
          <fpage>137</fpage>
          <lpage>145</lpage>
          <pub-id pub-id-type="doi">10.1172/JCI26121</pub-id>
          <pub-id pub-id-type="pmid">16357942</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Zelm</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Dongen</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Molecular diagnostics of primary immunodeficiencies: benefits and future challenges</article-title>
          <source>Adv Exp Med Biol</source>
          <year>2009</year>
          <volume>634</volume>
          <fpage>231</fpage>
          <lpage>241</lpage>
          <pub-id pub-id-type="pmid">19280862</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Verkaik</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Dekker</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Barendregt</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Pico-Knijnenburg</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Tezcan</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>vanDongen</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Gent</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
          <article-title>Defective Artemis nuclease is characterized by coding joints with microhomology in long palindromic-nucleotide stretches</article-title>
          <source>Eur J Immunol</source>
          <year>2007</year>
          <volume>37</volume>
          <fpage>3522</fpage>
          <lpage>3528</lpage>
          <pub-id pub-id-type="doi">10.1002/eji.200737624</pub-id>
          <pub-id pub-id-type="pmid">18034425</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burg</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Weemaes</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Preijers</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Brons</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Barendregt</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Tol</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Hoogerbrugge</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dongen</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>B-cell recovery after stem cell transplantation of Artemis-deficient SCID requires elimination of autologous bone marrow precursor-B-cells</article-title>
          <source>Haematologica</source>
          <year>2006</year>
          <volume>91</volume>
          <fpage>1705</fpage>
          <lpage>1709</lpage>
          <pub-id pub-id-type="pmid">17145611</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gent</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>McBlane</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Ramsden</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Sadofsky</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Hesse</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Gellert</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Initiation of V(D)J recombinations in a cell-free system by RAG1 and RAG2 proteins</article-title>
          <source>Curr Top Microbiol Immunol</source>
          <year>1996</year>
          <volume>217</volume>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="pmid">8787614</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gent</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Burg</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Non-homologous end-joining, a sticky affair</article-title>
          <source>Oncogene</source>
          <year>2007</year>
          <volume>26</volume>
          <fpage>7731</fpage>
          <lpage>7740</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.onc.1210871</pub-id>
          <pub-id pub-id-type="pmid">18066085</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Villa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Notarangelo</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Roifman</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>Omenn syndrome: inflammation in leaky severe combined immunodeficiency</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2008</year>
          <volume>122</volume>
          <fpage>1082</fpage>
          <lpage>1086</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2008.09.037</pub-id>
          <pub-id pub-id-type="pmid">18992930</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Villa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Santagata</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bozzi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Giliani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Frattini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Imberti</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gatta</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Ochs</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Schwarz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Notarangelo</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Vezzoni</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Spanopoulou</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Partial V(D)J recombination activity leads to Omenn syndrome</article-title>
          <source>Cell</source>
          <year>1998</year>
          <volume>93</volume>
          <fpage>885</fpage>
          <lpage>896</lpage>
          <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81448-8</pub-id>
          <pub-id pub-id-type="pmid">9630231</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Candotti</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Somatic mosaicism in primary immune deficiencies</article-title>
          <source>Curr Opin Allergy Clin Immunol</source>
          <year>2008</year>
          <volume>8</volume>
          <fpage>510</fpage>
          <lpage>514</lpage>
          <pub-id pub-id-type="doi">10.1097/ACI.0b013e328314b651</pub-id>
          <pub-id pub-id-type="pmid">18978464</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Toma</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Okamoto</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kasahara</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Koizumi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Agematsu</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shimada</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hayashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yachie</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Oligoclonal expansion of T lymphocytes with multiple second-site mutations leads to Omenn syndrome in a patient with RAG1-deficient severe combined immunodeficiency</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>106</volume>
          <fpage>2099</fpage>
          <lpage>2101</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2005-03-0936</pub-id>
          <pub-id pub-id-type="pmid">15845893</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walshe</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gaspar</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Thrasher</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Cale</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Gilmour</surname>
              <given-names>KC</given-names>
            </name>
          </person-group>
          <article-title>Signal transducer and activator of transcription 5 tyrosine phosphorylation for the diagnosis and monitoring of patients with severe combined immunodeficiency</article-title>
          <source>J Allergy Clin Immunol</source>
          <year>2009</year>
          <volume>123</volume>
          <fpage>505</fpage>
          <lpage>508</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaci.2008.11.041</pub-id>
          <pub-id pub-id-type="pmid">19203666</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-list>
          <def-item>
            <term>GVHD</term>
            <def>
              <p>Graft versus host disease</p>
            </def>
          </def-item>
          <def-item>
            <term>HSCT</term>
            <def>
              <p>Hematopoietic stem cell transplantation</p>
            </def>
          </def-item>
          <def-item>
            <term>NHEJ</term>
            <def>
              <p>Non-homologous end joining</p>
            </def>
          </def-item>
          <def-item>
            <term>PID</term>
            <def>
              <p>Primary immunodeficiency</p>
            </def>
          </def-item>
          <def-item>
            <term>SCID</term>
            <def>
              <p>Severe combined immunodeficiency</p>
            </def>
          </def-item>
        </def-list>
      </def-list>
    </glossary>
  </back>
</article>
